These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 9017889)

  • 1. Effects of antihypertensive therapy on glucose and lipid metabolism.
    Zehetgruber M; Christ G; Mundigler G; Gabriel H; Huber K
    Wien Klin Wochenschr; 1996 Dec; 108(24):775-80. PubMed ID: 9017889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antihypertensive therapy and modification of metabolic risk factors (glucose and lipid metabolism)].
    Klein W
    Z Kardiol; 1992 Jun; 81(6):295-302. PubMed ID: 1353932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril.
    Middeke M; Richter WO; Schwandt P; Holzgreve H
    Int J Clin Pharmacol Ther; 1997 Jun; 35(6):231-4. PubMed ID: 9208337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antihypertensive drug therapy and coronary heart disease risk.
    Schoenberger JA
    J Fam Pract; 1993 Jan; 36(1):70-3, 77-84. PubMed ID: 8419507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors and differential antihypertensive therapies.
    Os I
    Acta Med Austriaca; 1995; 22(3):45-7. PubMed ID: 8571750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antihypertensive therapy and coronary heart disease: significance of the effect of concomitant cardiovascular risk factors].
    Huber K; Wein W; Hornykewycz S; Zehetgruber M; Rauscha F
    Acta Med Austriaca; 1995; 22(3):48-51. PubMed ID: 8571751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
    Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
    J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk stratification for the prevention of cardiovascular complications of hypertension.
    Girerd X; Giral P
    Curr Med Res Opin; 2004 Jul; 20(7):1137-42. PubMed ID: 15265258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism.
    Pessina AC; Ciccariello L; Perrone F; Stoico V; Gussoni G; Scotti A; Muggeo M
    Nutr Metab Cardiovasc Dis; 2006 Mar; 16(2):137-47. PubMed ID: 16487914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
    Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
    J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertension and coronary artery disease: an unsolved problem.
    Ramsay LE; Yeo WW
    J Cardiovasc Pharmacol; 1991; 18 Suppl 2():S31-4. PubMed ID: 1725039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Drugs and arterial stiffness in hypertensive patients].
    Laurent S
    Drugs; 2003; 63 Spec No 1():1-8. PubMed ID: 12708878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of hypertension with consideration of metabolism. A challenge for current therapy of essential hypertension].
    Priebe P
    Fortschr Med; 1993 May; 111(13):227-30. PubMed ID: 8514226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypertension and CHD risk: whither alpha-1 blockers?
    Pandit RB
    Indian Heart J; 1996; 48(3):265-71. PubMed ID: 8755013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moxonidine in the treatment of overweight and obese patients with the metabolic syndrome: a postmarketing surveillance study.
    Sharma AM; Wagner T; Marsalek P
    J Hum Hypertens; 2004 Sep; 18(9):669-75. PubMed ID: 15269705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension: a new perspective in therapy and metabolic effect. Part I.
    Medina Ruiz A
    Bol Asoc Med P R; 1991 Sep; 83(9):399-401. PubMed ID: 1807274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease.
    Perreault S; Dorais M; Coupal L; Paradis G; Joffres MR; Grover SA
    CMAJ; 1999 May; 160(10):1449-55. PubMed ID: 10352634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and lipids.
    Sznajderman M
    Blood Press Suppl; 1996; 1():14-7. PubMed ID: 9162431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antihypertensive treatment--more dangerous than presumed?].
    Løchen ML
    Tidsskr Nor Laegeforen; 1991 Jan; 111(1):78-80. PubMed ID: 2000595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.